Study Overview: This study is for adults with a type of cancer called B cell non-Hodgkin lymphoma that hasn't responded to other treatments. It looks at a new treatment called CB-010, which uses special cells (CAR-T cells) that are changed in a lab to try to fight the cancer.
Participants will first receive medicines called cyclophosphamide and fludarabine to prepare their bodies. Then, they will get the CB-010 treatment. The study will check if this new treatment is safe and how well it works.
Key Points:- Duration: The study includes multiple visits to the clinic for treatment and monitoring.
- Eligibility: Participants must be 18 or older and meet certain health criteria.
- Risks: There are potential risks, and participants will be closely monitored for safety.
Before joining, consider the time commitment, your health status, and discuss with your doctor if this study might be a good fit for you.
How understandable was the trial content above?
Hard to understand
Easy to understand